Home › Funds › RICE HALL JAMES & ASSOCIATES, LLC › BCRX
RICE HALL JAMES & ASSOCIATES, LLC position in BCRX
BIOCRYST PHARMACEUTICALS INC · Health Care
RICE HALL JAMES & ASSOCIATES, LLC reported holding 2,268,561 shares of BCRX (BIOCRYST PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$18.9M, representing 1.00% of its reported portfolio and ranking #33 among its reported holdings. RICE HALL JAMES & ASSOCIATES, LLC has disclosed BCRX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How RICE HALL JAMES & ASSOCIATES, LLC's BCRX position evolved
RICE HALL JAMES & ASSOCIATES, LLC first disclosed a stake in BCRX in Q3 2023 at 2,275,638 shares (US$16.1M). The position peaked in Q2 2026 at 2,332,043 shares, worth US$23.3M. Across 13 filings, RICE HALL JAMES & ASSOCIATES, LLC increased the stake 5 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,268,561 shares valued at US$18.9M — a reduction of -63,482 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 2.28M | $16.11M | New |
| Q4 2023 | 2.20M | $13.16M | Reduce |
| Q1 2024 | 2.15M | $10.93M | Reduce |
| Q2 2024 | 2.08M | $12.85M | Reduce |
| Q3 2024 | 2.16M | $16.44M | Add |
| Q4 2024 | 2.08M | $15.65M | Reduce |
| Q1 2025 | 2.03M | $15.21M | Reduce |
| Q2 2025 | 2.06M | $18.46M | Add |
| Q3 2025 | 1.88M | $14.27M | Reduce |
| Q4 2025 | 1.90M | $14.85M | Add |
| Q1 2026 | 2.23M | $21.23M | Add |
| Q2 2026 | 2.33M | $23.32M | Add |
| Q3 2026 | 2.27M | $18.90M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BCRX and 13F data
BCRX (BIOCRYST PHARMACEUTICALS INC) is a Health Care company. 41 other funds we track also report a position in BCRX — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$158.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$151.0M), PERCEPTIVE ADVISORS LLC (US$103.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BCRX
- RA CAPITAL MANAGEMENT, L.P. 15.83M sh · $158.27M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 15.10M sh · $150.96M · Q2 2026
- PERCEPTIVE ADVISORS LLC 10.31M sh · $103.09M · Q2 2026
- TCG Crossover Management, LLC 11.02M sh · $91.80M · Q3 2026
- Vestal Point Capital, LP 8.30M sh · $83.00M · Q2 2026
- Jones Hill Capital LP 7.08M sh · $59.00M · Q3 2026
- Frazier Life Sciences Management, L.P. 4.01M sh · $40.09M · Q2 2026
- Kynam Capital Management, LP 2.52M sh · $21.01M · Q3 2026
- Nantahala Capital Management, LLC 2.10M sh · $17.50M · Q3 2026
More on RICE HALL JAMES & ASSOCIATES, LLC
FAQ
How long has RICE HALL JAMES & ASSOCIATES, LLC held BCRX?
RICE HALL JAMES & ASSOCIATES, LLC has disclosed BCRX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is RICE HALL JAMES & ASSOCIATES, LLC's current position in BCRX?
As of Q3 2026, RICE HALL JAMES & ASSOCIATES, LLC holds 2.27M shares of BCRX (BIOCRYST PHARMACEUTICALS INC), valued at $18.90M, representing 1.00% of its reported portfolio and ranking #33.
Has RICE HALL JAMES & ASSOCIATES, LLC been buying or selling BCRX?
In the latest 13F filing (Q3 2026), RICE HALL JAMES & ASSOCIATES, LLC reduced its position in BCRX. The position peaked in Q2 2026 at 2.33M shares.
Which other funds hold BCRX?
Other major institutional holders of BCRX include RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., PERCEPTIVE ADVISORS LLC, among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.